Association Between Effectiveness of Mirikizumab and UC Patients with High Neutrophilic Infiltration in Epithelium of the Colonic Mucosa

Launched by SHOWA INAN GENERAL HOSPITAL · Oct 1, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring the effects of a medication called Mirikizumab on patients with moderate to severe ulcerative colitis (UC) who have not responded well to other treatments. The study specifically looks at patients who show high levels of certain white blood cells, called neutrophils, in their colon tissue, which can indicate active inflammation. The goal is to see if Mirikizumab can help improve symptoms, reduce inflammation, and promote healing in these patients.

To be eligible for this trial, participants must be adults with active ulcerative colitis confirmed by an endoscopy, which is a procedure that allows doctors to view the inside of the colon. However, individuals with long-term illnesses, colorectal cancer, or infections in the colon cannot participate. Those who join the study can expect to receive Mirikizumab and will be monitored for improvements in their condition through various assessments. This research aims to provide more options for patients who are struggling with their UC treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • They were endoscopically active ulcerative colitis patients.
• Exclusion Criteria:
• • the presence of a long-term illness, colorectal cancer, or infectious colitis